Memantin Hcs (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptors in a non‑competitive manner, preventing excessive calcium influx that can cause neuronal damage. By moderating excitotoxicity, it supports neuronal health and helps maintain synaptic transmission in patients with Alzheimer’s disease.

The appropriate dose of Memantin Hcs is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments may be needed for special populations, and patients should follow the prescriber’s instructions.

The safety of memantine during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (e.g., donepezil) act by increasing acetylcholine levels. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit.

Memantin Hcs should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Memantin Hcs is taken orally, usually as a tablet, with or without food. The exact administration schedule, including titration and maintenance doses, is determined by the prescribing clinician based on individual patient needs.

Serious risks include the potential for seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction, and emergence of suicidal thoughts. Patients should be monitored regularly for these events, especially during treatment initiation and dose changes.

Memantin Hcs is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists, as these conditions increase the risk of adverse effects.